cfDNA Special D cfDNA Extraction Cell Free DNA Extraction

Description

Cell-free DNA (cfDNA) refers to short, fragmented DNA molecules that are released into the bloodstream and other bodily fluids following cell death (apoptosis or necrosis). These fragments, typically ranging from 160 to 200 base pairs in length, provide a non-invasive window into the physiological and pathological state of the body.
Our cell-free DNA (cfDNA) Extraction Magnetic Beads are engineered for the highly efficient and reliable isolation of short-fragment, low-concentration cfDNA from plasma, serum, and other liquid biopsies. Utilizing a specialized surface chemistry, these beads demonstrate superior binding affinity for dsDNA and ssDNA across a wide size range, ensuring maximum recovery of the critical 160-180 bp fraction that is rich in biological information. This technology is the cornerstone for robust and reproducible liquid biopsy workflows, enabling downstream applications in non-invasive prenatal testing (NIPT), cancer early detection, and transplant monitoring.

Specification

Features

• Optimized for Short Fragments: Superior recovery efficiency for short, fragmented cfDNA, minimizing the loss of critical biomarkers.

• High Sensitivity & Yield: Designed for maximum yield from low-input and low-concentration samples, which is essential for liquid biopsy applications.

• Exceptional Purity: Effectively removes contaminants such as proteins, salts, and cellular genomic DNA, providing clean cfDNA ideal for sensitive downstream assays like NGS and dPCR.

• Robust & Automation-Ready: Exhibits excellent chemical stability and dispersion, ensuring batch-to-batch consistency and seamless integration into automated, high-throughput nucleic acid extraction systems.

• Rapid Workflow: Streamlines the extraction process, reducing hands-on time and enabling quick turnaround from sample to analysis.

This product is an indispensable tool for clinical researchers and diagnostic developers who require the highest standards of performance in their cfDNA analysis pipeline.

Application

Nucleic acid extraction and purification, suitable for serum/plasma free DNA/RNA

The analysis of cfDNA, particularly the subset derived from tumors known as circulating tumor DNA (ctDNA), has revolutionized diagnostic medicine. Its key applications encompass:

• Non-Invasive Prenatal Testing (NIPT): The detection of fetal cfDNA in maternal plasma allows for the early screening of chromosomal aneuploidies without any risk to the fetus.

• Liquid Biopsy in Oncology: This is a transformative approach for cancer management. It enables early cancer detection, identification of targetable mutations for personalized therapy, real-time monitoring of treatment response, and early detection of minimal residual disease (MRD) and recurrence.

• Transplant Monitoring: In organ transplant recipients, the quantification of donor-derived cfDNA serves as a highly sensitive, non-invasive biomarker for assessing graft rejection.

• Research and Emerging Diagnostics: cfDNA analysis is being actively explored in other areas, including the study of autoimmune diseases and sepsis.

As a cornerstone of liquid biopsy, cfDNA analysis provides a powerful tool for precision medicine, offering critical insights that were previously inaccessible without invasive procedures.